These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32199895)

  • 1. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Eng VA; Solis DC; Gorell ES; Choi S; Nazaroff J; Li S; de Souza MP; Murrell DF; Marinkovich MP; Tang JY
    J Am Acad Dermatol; 2021 Nov; 85(5):1161-1167. PubMed ID: 32199895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
    Tang JY; Marinkovich MP; Lucas E; Gorell E; Chiou A; Lu Y; Gillon J; Patel D; Rudin D
    Orphanet J Rare Dis; 2021 Apr; 16(1):175. PubMed ID: 33849616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Fulchand S; Harris N; Li S; Barriga M; Gorell E; De Souza M; Murrell D; Marinkovich MP; Krishna Yenamandra V; Tang JY
    Pediatr Dermatol; 2021 Sep; 38(5):1198-1201. PubMed ID: 34515355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.
    So JY; Fulchand S; Wong CY; Li S; Nazaroff J; Gorell ES; de Souza MP; Murrell DF; Teng JM; Chiou AS; Tang JY
    Orphanet J Rare Dis; 2022 Jul; 17(1):270. PubMed ID: 35841105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
    Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
    J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
    Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
    Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study.
    Mellerio JE; Pillay EI; Ledwaba-Chapman L; Bisquera A; Robertson SJ; Papanikolaou M; McGrath JA; Wang Y; Martinez AE; Jeffs E
    Orphanet J Rare Dis; 2023 Aug; 18(1):235. PubMed ID: 37559055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
    So JY; Nazaroff J; Iwummadu CV; Harris N; Gorell ES; Fulchand S; Bailey I; McCarthy D; Siprashvili Z; Marinkovich MP; Tang JY; Chiou AS
    Orphanet J Rare Dis; 2022 Oct; 17(1):377. PubMed ID: 36253825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa.
    Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF;
    Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
    Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
    JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
    Eichstadt S; Barriga M; Ponakala A; Teng C; Nguyen NT; Siprashvili Z; Nazaroff J; Gorell ES; Chiou AS; Taylor L; Khuu P; Keene DR; Rieger K; Khosla RK; Furukawa LK; Lorenz HP; Marinkovich MP; Tang JY
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES).
    Jeffs E; Pillay EI; Ledwaba-Chapman L; Bisquera A; Robertson SJ; McGrath JA; Wang Y; Martinez AE; Mellerio JE
    Orphanet J Rare Dis; 2024 Oct; 19(1):375. PubMed ID: 39394129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.
    Ebens CL; McGrath JA; Tamai K; Hovnanian A; Wagner JE; Riddle MJ; Keene DR; DeFor TE; Tryon R; Chen M; Woodley DT; Hook K; Tolar J
    Br J Dermatol; 2019 Dec; 181(6):1238-1246. PubMed ID: 30843184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions.
    De Gregorio C; Catalán E; Garrido G; Morandé P; Bennett JC; Muñoz C; Cofré G; Huang YL; Cuadra B; Murgas P; Calvo M; Altermatt F; Yubero MJ; Palisson F; South AP; Ezquer M; Fuentes I
    Biol Res; 2023 May; 56(1):23. PubMed ID: 37161592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases.
    Hwang A; Kwon A; Miller CH; Reimer-Taschenbrecker A; Paller AS
    Orphanet J Rare Dis; 2024 May; 19(1):206. PubMed ID: 38769503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrochemotherapy, a local treatment for squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
    Bartolo J; Farricha V; Carvalhal S; Moura C; Abecasis N
    Dermatol Ther; 2020 Nov; 33(6):e14093. PubMed ID: 32720460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional genotype-phenotype associations in recessive dystrophic epidermolysis bullosa.
    So JY; Nazaroff J; Yenamandra VK; Gorell ES; Harris N; Fulchand S; Eid E; Dolorito JA; Marinkovich MP; Tang JY
    J Am Acad Dermatol; 2024 Sep; 91(3):448-456. PubMed ID: 38735484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCB5
    Dieter K; Niebergall-Roth E; Daniele C; Fluhr S; Frank NY; Ganss C; Kiritsi D; McGrath JA; Tolar J; Frank MH; Kluth MA
    Cytotherapy; 2023 Jul; 25(7):782-788. PubMed ID: 36868990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa.
    Popp C; Miller W; Eide C; Tolar J; McGrath JA; Ebens CL
    J Invest Dermatol; 2024 Sep; 144(9):1943-1953. PubMed ID: 38613531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa.
    Solis DC; Gorell ES; Teng C; Barriga M; Nazaroff J; Li S; Subica A; Lu Y; Marinkovich MP; Tang JY
    Pediatr Dermatol; 2021 May; 38(3):704-706. PubMed ID: 33749033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.